Next-generation Sequencing for Diagnosis of Thoracic Aortic Aneurysms and Dissections: Diagnostic Yield, Novel Mutations and Genotype Phenotype Correlations

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2016 May 6

PMID 27146836

Citations 29

Authors

J K Poninska

Z T Bilinska

M Franaszczyk

E Michalak

M Rydzanicz

E Szpakowski

A Pollak

B Milanowska

G Truszkowska

P Chmielewski

A Sioma

H Janaszek-Sitkowska

A Klisiewicz

I Michalowska

M Makowiecka-Ciesla

P Kolsut

P Stawinski

B Foss-Nieradko

M Szperl

J Grzybowski

P Hoffman

A Januszewicz

M Kusmierczyk

R Ploski

Affiliations

Soon will be listed here.

Abstract

Background: Thoracic aortic aneurysms and dissections (TAAD) are silent but possibly lethal condition with up to 40 % of cases being hereditary. Genetic background is heterogeneous. Recently next-generation sequencing enabled efficient and cost-effective examination of gene panels. Aim of the study was to define the diagnostic yield of NGS in the 51 TAAD patients and to look for genotype-phenotype correlations within families of the patients with TAAD.

Methods: 51 unrelated TAAD patients were examined by either whole exome sequencing or TruSight One sequencing panel. We analyzed rare variants in 10 established thoracic aortic aneurysms-associated genes. Whenever possible, we looked for co-segregation in the families. Kaplan-Meier survival curve was constructed to compare the event-free survival depending on genotype. Aortic events were defined as acute aortic dissection or first planned aortic surgery.

Results And Discussion: In 21 TAAD patients we found 22 rare variants, 6 (27.3 %) of these were previously reported, and 16 (73.7 %) were novel. Based on segregation data, functional analysis and software estimations we assumed that three of novel variants were causative, nine likely causative. Remaining four were classified as of unknown significance (2) and likely benign (2). In all, 9 (17.6 %) of 51 probands had a positive result when considering variants classified as causative only and 18 (35.3 %) if likely causative were also included. Genotype-positive probands (n = 18) showed shorter mean event free survival (41 years, CI 35-46) than reference group, i.e. those (n = 29) without any plausible variant identified (51 years, CI 45-57, p = 0.0083). This effect was also found when the 'genotype-positive' group was restricted to probands with 'likely causative' variants (p = 0.0092) which further supports pathogenicity of these variants. The mean event free survival was particularly low (37 years, CI 27-47) among the probands with defects in the TGF beta signaling (p = 0.0033 vs. the reference group).

Conclusions: This study broadens the spectrum of genetic background of thoracic aneurysms and dissections and supports its potential role as a prognostic factor in the patients with the disease.

Citing Articles

Genetic insights from a Brazilian cohort of aortopathies through targeted next-generation sequencing and FBN1 direct sequencing.

Rocha Ferreira J, Passarelli Pereira J, Arpini Botelho A, do Nascimento Aprijo D, Machado Melo M, Cramer Veiga Rey H Sci Rep. 2024; 14(1):27172.

PMID: 39511342 PMC: 11543835. DOI: 10.1038/s41598-024-78788-3.

Identification of Genetic Variants Associated with Hereditary Thoracic Aortic Diseases (HTADs) Using Next Generation Sequencing (NGS) Technology and Genotype-Phenotype Correlations.

Butnariu L, Russu G, Luca A, Sandu C, Trandafir L, Vasiliu I Int J Mol Sci. 2024; 25(20).

PMID: 39456956 PMC: 11508433. DOI: 10.3390/ijms252011173.

Prevalence and Influence of Genetic Variants on Follow-Up Results in Patients Surviving Thoracic Aortic Therapy.

Ghazy T, Elzanaty N, Lackner H, Irqsusi M, Rastan A, Behrendt C J Clin Med. 2024; 13(17).

PMID: 39274466 PMC: 11396620. DOI: 10.3390/jcm13175254.

Evaluation of the Value of Histological Examination for the Prediction of Genetic Thoracic Proximal Aortopathies.

Mahlmann A, Rodionov R, Behrendt C, Leip J, Lackner H, Eraqi M J Clin Med. 2024; 13(7).

PMID: 38610603 PMC: 11012398. DOI: 10.3390/jcm13071838.

Prevalence of Genetic Variants and Deep Phenotyping in Patients with Thoracic Aortic Aneurysm and Dissection: A Cross-Sectional Single-Centre Cohort Study.

Mahlmann A, Elzanaty N, Saleh M, Irqsusi M, Rastan A, Leip J J Clin Med. 2024; 13(2).

PMID: 38256594 PMC: 10816602. DOI: 10.3390/jcm13020461.

References

Soylen B, Singh K, Abuzainin A, Rommel K, Becker H, Arslan-Kirchner M . Prevalence of dural ectasia in 63 gene-mutation-positive patients with features of Marfan syndrome type 1 and Loeys-Dietz syndrome and report of 22 novel FBN1 mutations. Clin Genet. 2009; 75(3):265-70. DOI: 10.1111/j.1399-0004.2008.01126.x. View

Collod-Beroud G, Le Bourdelles S, Ades L, Ala-Kokko L, Booms P, Boxer M . Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat. 2003; 22(3):199-208. DOI: 10.1002/humu.10249. View

Naz S, Fatima A . Amplification of GC-rich DNA for high-throughput family-based genetic studies. Mol Biotechnol. 2012; 53(3):345-50. PMC: 3581729. DOI: 10.1007/s12033-012-9559-y. View

Comeglio P, Johnson P, Arno G, Brice G, Evans A, Aragon-Martin J . The importance of mutation detection in Marfan syndrome and Marfan-related disorders: report of 193 FBN1 mutations. Hum Mutat. 2007; 28(9):928. DOI: 10.1002/humu.9505. View

Tiecke F, Katzke S, Booms P, Robinson P, Neumann L, Godfrey M . Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype-phenotype correlations in FBN1 exons 24-40. Eur J Hum Genet. 2001; 9(1):13-21. DOI: 10.1038/sj.ejhg.5200582. View

Liu W, Oefner P, Qian C, Odom R, Francke U . Denaturing HPLC-identified novel FBN1 mutations, polymorphisms, and sequence variants in Marfan syndrome and related connective tissue disorders. Genet Test. 1997; 1(4):237-42. DOI: 10.1089/gte.1997.1.237. View

Ploski R, Pollak A, Muller S, Franaszczyk M, Michalak E, Kosinska J . Does p.Q247X in TRIM63 cause human hypertrophic cardiomyopathy?. Circ Res. 2014; 114(2):e2-5. DOI: 10.1161/CIRCRESAHA.114.302662. View

Attanasio M, Pratelli E, Porciani M, Evangelisti L, Torricelli E, Pellicano G . Dural ectasia and FBN1 mutation screening of 40 patients with Marfan syndrome and related disorders: role of dural ectasia for the diagnosis. Eur J Med Genet. 2013; 56(7):356-60. DOI: 10.1016/j.ejmg.2013.04.006. View

van de Laar I, van der Linde D, Oei E, Bos P, Bessems J, Bierma-Zeinstra S . Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J Med Genet. 2011; 49(1):47-57. DOI: 10.1136/jmedgenet-2011-100382. View

10.

Ogawa N, Imai Y, Takahashi Y, Nawata K, Hara K, Nishimura H . Evaluating Japanese patients with the Marfan syndrome using high-throughput microarray-based mutational analysis of fibrillin-1 gene. Am J Cardiol. 2011; 108(12):1801-7. DOI: 10.1016/j.amjcard.2011.07.053. View

11.

Milewicz D, Carlson A, Regalado E . Genetic testing in aortic aneurysm disease: PRO. Cardiol Clin. 2010; 28(2):191-7. PMC: 3615454. DOI: 10.1016/j.ccl.2010.01.017. View

12.

Aalberts J, Schuurman A, Pals G, Hamel B, Bosman G, Hilhorst-Hofstee Y . Recurrent and founder mutations in the Netherlands: Extensive clinical variability in Marfan syndrome patients with a single novel recurrent fibrillin-1 missense mutation. Neth Heart J. 2010; 18(2):85-9. PMC: 2828568. DOI: 10.1007/BF03091743. View

13.

Faivre L, GORLIN R, Wirtz M, Godfrey M, Dagoneau N, Samples J . In frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani syndrome. J Med Genet. 2003; 40(1):34-6. PMC: 1735272. DOI: 10.1136/jmg.40.1.34. View

14.

Loeys B, Chen J, Neptune E, Judge D, Podowski M, Holm T . A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005; 37(3):275-81. DOI: 10.1038/ng1511. View

15.

Aalberts J, van Tintelen J, Meijboom L, Polko A, Jongbloed J, van der Wal H . Relation between genotype and left-ventricular dilatation in patients with Marfan syndrome. Gene. 2013; 534(1):40-3. DOI: 10.1016/j.gene.2013.10.033. View

16.

Dietz H, Cutting G, Pyeritz R, Maslen C, Sakai L, Corson G . Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991; 352(6333):337-9. DOI: 10.1038/352337a0. View

17.

Maslen C, Corson G, Maddox B, Glanville R, Sakai L . Partial sequence of a candidate gene for the Marfan syndrome. Nature. 1991; 352(6333):334-7. DOI: 10.1038/352334a0. View

18.

Kroes H, Pals G, van Essen A . Ehlers-Danlos syndrome type IV: unusual congenital anomalies in a mother and son with a COL3A1 mutation and a normal collagen III protein profile. Clin Genet. 2003; 63(3):224-7. DOI: 10.1034/j.1399-0004.2003.00047.x. View

19.

Lee B, Godfrey M, Vitale E, Hori H, Mattei M, Sarfarazi M . Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. Nature. 1991; 352(6333):330-4. DOI: 10.1038/352330a0. View

20.

Arslan-Kirchner M, Epplen J, Faivre L, Jondeau G, Schmidtke J, De Paepe A . Clinical utility gene card for: Loeys-Dietz syndrome (TGFBR1/2) and related phenotypes. Eur J Hum Genet. 2011; 19(10). PMC: 3190257. DOI: 10.1038/ejhg.2011.68. View